BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28454268)

  • 1. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.
    Liu X; Feng M; Zheng G; Gu Y; Wang C; He Z
    Oncol Lett; 2017 Mar; 13(3):1398-1405. PubMed ID: 28454268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cells.
    Liu X; Wang C; Gu Y; Zhang Z; Zheng G; He Z
    Mol Cell Biochem; 2015 Jan; 398(1-2):175-83. PubMed ID: 25260657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer.
    Jia X; Zhang Z; Luo K; Zheng G; Lu M; Song Y; Liu H; Qiu H; He Z
    Sci Rep; 2017 Jun; 7(1):3744. PubMed ID: 28623290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and biochemical characterization of a novel protein-tongue cancer chemotherapy resistance-associated protein1 (TCRP1).
    Peng B; Yi S; Gu Y; Zheng G; He Z
    Protein Expr Purif; 2012 Apr; 82(2):360-7. PubMed ID: 22365988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1.
    Wang C; Liu H; Qiu Q; Zhang Z; Gu Y; He Z
    Oncogenesis; 2017 Apr; 6(4):e323. PubMed ID: 28436990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).
    Gu Y; Zhang Z; Yin J; Ye J; Song Y; Liu H; Xiong Y; Lu M; Zheng G; He Z
    J Exp Clin Cancer Res; 2017 Aug; 36(1):114. PubMed ID: 28859669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.
    Peng B; Gu Y; Xiong Y; Zheng G; He Z
    PLoS One; 2012; 7(12):e51413. PubMed ID: 23251525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.
    Oguri T; Kunii E; Fukuda S; Sone K; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Biomed Rep; 2016 Nov; 5(5):639-643. PubMed ID: 27882231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L; Yu H; Zhang W; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.
    Tashiro T; Kawada Y; Sakurai Y; Kidani Y
    Biomed Pharmacother; 1989; 43(4):251-60. PubMed ID: 2790145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a.
    Liu H; Jia X; Luo K; Chen X; Zhang Z; Chen D; Gu Y; He Z; Zheng G
    Oncogenesis; 2022 Apr; 11(1):19. PubMed ID: 35459265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC).
    Li ZH; Zheng R; Chen JT; Jia J; Qiu M
    J Cancer; 2016; 7(14):2085-2092. PubMed ID: 27877224
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
    Xie D; Yin RT; Li KM; Xiao P; Tong LX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.